Publications by authors named "Ronald Rose"

Claim this Profile
P
Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499.
Chunfu Wang, Haichang Huang, Lourdes Valera, Kyle Parcella, Christiana Iwuagwu, Ronald E Rose

Antimicrob Agents Chemother· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
Margaret Gartland, Eugene Stewart, Nannan Zhou, Zhufang Li, Ronald Rose

Antiviral Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
Ronald Rose, Margaret Gartland, Zhufang Li, Nannan Zhou, Mark Cockett

AIDS· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
Ronald E Rose, Dennis Hernandez, Paul J Falk, Karen Ericson, Nannan Zhou

Hepatol Commun· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.
Michael J Wichroski, Jie Fang, Betsy J Eggers, Ronald E Rose, Charles E Mazzucco

PLoS One· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.
Robert A Fridell, Dike Qiu, Lourdes Valera, Chunfu Wang, Ronald E Rose

J Virol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel small molecule inhibitor of hepatitis C virus entry.
Carl J Baldick, Michael J Wichroski, Annapurna Pendri, Ann W Walsh, Jie Fang, Ronald E Rose

PLoS Pathog· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates.
Jie Fang, Michael J Wichroski, Steven M Levine, Carl J Baldick, Charles E Mazzucco, Ronald E Rose

Antimicrob Agents Chemother· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.
Daniel J Tenney, Ronald E Rose, Carl J Baldick, Kevin A Pokornowski, Betsy J Eggers

Hepatology· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
Carl J Baldick, Betsy J Eggers, Jie Fang, Steven M Levine, Kevin A Pokornowski, Ronald E Rose

J Hepatol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance.
Carl J Baldick, Daniel J Tenney, Charles E Mazzucco, Betsy J Eggers, Ronald E Rose

Hepatology· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
Herbert E Klei, Kevin Kish, Pin-Fang M Lin, Qi Guo, Jacques Friborg, Ronald E Rose

J Virol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of hepatitis B virus polymerase by entecavir.
David R Langley, Ann W Walsh, Carl J Baldick, Betsy J Eggers, Ronald E Rose

J Virol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Daniel J Tenney, Ronald E Rose, Carl J Baldick, Steven M Levine, Kevin A Pokornowski

Antimicrob Agents Chemother· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Richard J Colonno, Ronald Rose, Carl J Baldick, Steven Levine, Kevin Pokornowski

Hepatology· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
Ting-Tsung Chang, Robert G Gish, Stephanos J Hadziyannis, Janusz Cianciara, Mario Rizzetto, Ronald E Rose

Gastroenterology· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Joseph Yanchunas, David R Langley, Li Tao, Ronald E Rose, Jacques Friborg

Antimicrob Agents Chemother· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replication-competent chimeric hepatitis C virus subgenomic replicons.
Julie A Lemm, Mengping Liu, Ronald E Rose, Robert Fridell, Donald R O'Boyle Ii

Intervirology· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
Richard Colonno, Ronald Rose, Colin McLaren, Alexandra Thiry, Neil Parkin

J Infect Dis· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
Qi Guo, Hsu-Tso Ho, Ira Dicker, Li Fan, Nannan Zhou, Ronald E Rose

J Virol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
Pin-Fang Lin, Wade Blair, Tao Wang, Timothy Spicer, Qi Guo, Ronald Rose

Proc Natl Acad Sci U S A· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
Tao Wang, Zhongxing Zhang, Owen B Wallace, Milind Deshpande, Haiquan Fang, Ronald Rose

J Med Chem· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis